

Literaturübersicht: Medizinalcannabis bei Morbus Parkinson

Stand: 31.01.2022, SGCM-SSCM

Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. *Neurology*. 2004;63:1245–50.

Chagas MHN, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM, et al. Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. *J Psychopharmacol Oxf Engl*. 2014;28:1088–98.

Chaudhuri KR, Schapira AHV. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. *Lancet Neurol*. 2009;8:464–74.

Covey D, Mateo Y, Sulzer D, Cheer JF, Lovinger DM. Endocannabinoid modulation of dopamine neurotransmission. *Neuropharmacology*. 2017;124:52–61.

Feeney MP, Bega D, Kluger BM, Stoessl AJ, Evers CM, De Leon R, et al. Weeding through the haze: a survey on cannabis use among people living with Parkinson's disease in the US. *NPJ Park Dis*. 2021;7:21.

Fernández-Ruiz J, García C, Sagredo O, Gómez-Ruiz M, de Lago E. The endocannabinoid system as a target for the treatment of neuronal damage. *Expert Opin Ther Targets*. 2010;14:387–404.

Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. *Mov Disord Off J Mov Disord Soc*. 2002;17:1180–7.

Frankel JP, Hughes A, Lees AJ, Stern GM. Marijuana for parkinsonian tremor. *J Neurol Neurosurg Psychiatry*. 1990;53:436.

Howes J, Osgood P. The effect of delta9-tetrahydrocannabinol on the uptake and release of 14C-dopamine from crude striatal synaptosomes; preparations. *Neuropharmacology*. 1974;13:1109–14.

Kalia LV, Kalia SK, Lang AE. Disease-modifying strategies for Parkinson's disease. *Mov Disord Off J Mov Disord Soc*. 2015;30:1442–50.

Kelsey JE, Harris O, Cassin J. The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. *Behav Brain Res*. 2009;203:304–7.

Kindred JH, Li K, Ketelhut NB, Proessl F, Fling BW, Honce JM, et al. Cannabis use in people with Parkinson's disease and Multiple Sclerosis: A web-based investigation. *Complement Ther Med*. 2017;33:99–104.

Leehey MA, Liu Y, Hart F, Epstein C, Cook M, Sillau S, et al. Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study. *Cannabis Cannabinoid Res*. 2020;5:326–36.

Lotan I, Treves TA, Roditi Y, Djaldetti R. Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. *Clin Neuropharmacol*. 2014;37:41–4.

Meschler JP, Howlett AC, Madras BK. Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. *Psychopharmacology (Berl)*. 2001;156:79–85.

Mesnager V, Houeto JL, Bonnet AM, Clavier I, Arnulf I, Cattelin F, et al. Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. *Clin Neuropharmacol*. 2004;27:108–10.

Peball M, Krismer F, Knaus H-G, Djamshidian A, Werkmann M, Carbone F, et al. Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone. *Ann Neurol*. 2020;88:712–22.

Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. *Prostaglandins Leukot Essent Fatty Acids*. 2002;66:101–21.

Pringsheim T, Jette N, Frolkis A, Steeves TDL. The prevalence of Parkinson's disease: a systematic review and meta-analysis. *Mov Disord Off J Mov Disord Soc*. 2014;29:1583–90.

Rascol O, Perez-Lloret S, Ferreira JJ. New treatments for levodopa-induced motor complications. *Mov Disord Off J Mov Disord Soc*. 2015;30:1451–60.

Schrag A, Sauerbier A, Chaudhuri KR. New clinical trials for nonmotor manifestations of Parkinson's disease. *Mov Disord Off J Mov Disord Soc.* 2015;30:1490–504.

Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. *Neurology.* 2001;57:2108–11.

Thanabalasingam SJ, Ranjith B, Jackson R, Wijeratne DT. Cannabis and its derivatives for the use of motor symptoms in Parkinson's disease: a systematic review and meta-analysis. *Ther Adv Neurol Disord.* 2021;14.

Venderová K, Růžicka E, Vorísek V, Visnovský P. Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms. *Mov Disord Off J Mov Disord Soc.* 2004;19:1102–6.

Yenilmez F, Fründt O, Hidding U, Buhmann C. Cannabis in Parkinson's Disease: The Patients' View. *J Park Dis.* 2021;11:309–21.

Zuardi AW, Crippa J a. S, Hallak JEC, Pinto JP, Chagas MHN, Rodrigues GGR, et al. Cannabidiol for the treatment of psychosis in Parkinson's disease. *J Psychopharmacol Oxf Engl.* 2009;23:979–83.